Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1985004584) METHOD OF INHIBITING AND INDUCING HUMAN PLATELET AGGREGATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1985/004584 International Application No.: PCT/US1985/000589
Publication Date: 24.10.1985 International Filing Date: 08.04.1985
IPC:
C07K 14/75 (2006.01) ,C07K 19/00 (2006.01) ,A61K 38/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
745
Blood coagulation or fibrinolysis factors
75
Fibrinogen
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
19
Hybrid peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
Applicants:
NEW ENGLAND DEACONESS HOSPITAL [US/US]; 185 Pilgrim Road Boston, MA 02215, US
Inventors:
HAWIGER, Jack, J.; US
TIMMONS, Sheila; US
LUKAS, Thomas, J.; US
KLOCZEWIAK, Marek; US
Agent:
LAPPIN, Mark, G. @; Lahive & Cockfield 60 State Street Boston, MA 02109, US
Priority Data:
599,47710.04.1984US
Title (EN) METHOD OF INHIBITING AND INDUCING HUMAN PLATELET AGGREGATION
(FR) PROCEDE D'INHIBITION ET D'INDUCTION DE L'AGREGATION DES THROMBOCYTES HUMAINS
Abstract:
(EN) A method of inhibiting thrombin or ADP-induced human platelet aggregation by fibrinogen has been developed. The administration of the small molecular weight peptide or the synthetic inhibitory molecule of the invention significantly inhibits thrombin or ADP-modified human platelets binding of fibrinogen, a plasma protein necessary for platelet aggregation. The method of the invention is useful for inhibiting of the formation of hemostatic platelet plugs and of the initiation of thrombotic lesions. The blockage caused by hemostatic platelet plugs and the damage caused by thrombotic lesions are major factors in heart disease and stroke. The invention also includes a method of inducing the formation of thrombin or ADP-modified platelet aggregates by administration of a synthetic aggregating molecule which represents a functional substitute for fibrinogen.
(FR) Procédé d'inhibition de l'agrégation des thrombocytes humains induite par l'ADP ou la thrombine par un fibrinogène. L'administration de la molécule inhibitrice synthétique ou du peptide de faible poids moléculaire de la présente invention inhibe de manière significative la liaison des thrombocytes humains modifiés par l'ADP ou la thrombine au fibrinogène, une protéine plasmatique nécessaire pour l'agrégation des thrombocytes. Le procédé de la présente invention est utile pour inhiber la formation de bouchons de thrombocytes hémostatiques et l'initiation des lésions thrombotiques. Le blocage provoqué par les bouchons de thrombocytes hémostatiques et l'endommagement dû aux lésions thrombotiques sont des facteurs importants des affections cardiaques et des apoplexies. La présente invention comporte en outre un procédé d'induction de la formation d'agrégats de thrombocytes modifiés par l'ADP ou la thrombine grâce à l'administration d'une molécule d'agrégation synthétique représentant un substitut fonctionnel du fibrinogène.
Designated States: AU, JP
European Patent Office (AT, BE, CH, DE, FR, GB, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0180595AU1985041596